Diaceutics PLCLSE: DXRX

Diaceutics: Block Listing Return

· Issued by Diaceutics PLC

Summary by 6ix AI

Diaceutics PLC, which works with biopharma companies on diagnostic-driven therapies, issued 316,969 ordinary shares under its employee share plans between April 7, 2026 and October 6, 2026. The shares came from a block listing, a set of shares admitted to trading in advance and issued as needed.

Key details

  • The plans are the UK and Global Share Incentive Plan for employees, the Employee Share Option Plan and the Unapproved Share Option Plan, which includes long-term incentive awards.
  • The balance under the plans was 1,233,063 ordinary shares of £0.002 each at the previous return, and 916,094 ordinary shares not yet issued at the end of the period. The block listing was not increased.
  • The block listing originally covered 1,500,000 ordinary shares, admitted on October 6, 2023.
  • Diaceutics had 85,234,252 ordinary shares of £0.002 each in issue at the end of the period.
  • The return is required under the rules of AIM (Alternative Investment Market), the London Stock Exchange market where Diaceutics trades as DXRX.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/block-listing-return-62

Watch Diaceutics' latest callDiaceutics (LSE:DXRX) Q4 2024 Earnings Call · Replay · May 13, 2025Read the transcript of Diaceutics (LSE:DXRX) Q4 2024 Earnings Call

Diaceutics PLC

BLOCK LISTING RETURN

New York, Belfast and London, 7 October 2026 - Diaceutics PLC (AIM: DXRX), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, gives the below information required by Schedule 6 of the AIM Rules for Companies in connection with the UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long term incentive awards.

Name of applicant:

Diaceutics PLC

Name of scheme:

UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long-term incentive awards.

Period of return:

From:

7 April 2026

To:

6 October 2026

Balance under scheme from previous return:

1,233,063 Ordinary Shares of £0.002 each

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

N/A

Number of securities issued/allotted under schemes during period:

316,969 Ordinary Shares

Balance under scheme not yet issued/allotted at end of period

916,094 Ordinary Shares

Number and class of securities originally listed and the date of admission

1,500,000 Ordinary Shares on 6 October 2023

Total number of securities in issue at the end of the period

85,234,252 Ordinary Shares of £0.002 each

Name of contact:

Nick Roberts

Telephone number of contact:

As below

Enquiries: 

Diaceutics PLC   

Nick Roberts, Chief Financial Officer  

Tel: +44 (0)28 9040 6500

[email protected]

Canaccord Genuity Limited (Nomad & Broker) 

Tel: +44 (0)20 7523 8000

Simon Bridges, Andrew Potts, Harry Rees

About Diaceutics

At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.

Diaceutics PLC on 6ix

Story so far

Earlier from Diaceutics

Later from Diaceutics

All Diaceutics news releases